newsfilter
← Latest News
Business Wire·

Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th

CMPS
  • Compass Pathways plc (Nasdaq: CMPS) management will attend the Jefferies Global Healthcare Conference on November 18 & 19, 2026.
  • A fireside chat will take place on November 18 at 9:00am GMT, with a live audio webcast available at the provided link.
  • A panel discussion will occur on November 19 at 10:30am GMT, with a live audio webcast available at the provided link.
  • Replays of both webcasts will be accessible for 30 days post-event via the Investors section of the Compass website.
  • The company is developing COMP360 psilocybin, an investigational treatment for treatment-resistant depression (TRD) & post-traumatic stress disorder (PTSD).
  • COMP360 holds Breakthrough Therapy designation from the U.S. FDA & Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD.
  • Compass is conducting the world's largest classic psychedelic clinical program in TRD & is executing a late-stage trial for PTSD.
  • The company aims to advance psychiatry treatments with rapid onset, sustained durability, & infrequent dosing.
  • Compass Pathways is headquartered in London, UK, with a U.S. office in New Jersey.
  • Media inquiries should be directed to Dana Sultan-Rothman, while investor inquiries should go to Stephen Schultz.